报价延迟最少15分钟:2025/07/21 18:48 EDT
盘后时段
|
||||
|
17.7 
|
|
|
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
17.7
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-2.73/-3.15
|
|
企业价值
3.06B
|
| 资产负债 |
|
每股账面净值
4.14
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
报价延迟最少15分钟：2025/07/21 18:48 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Immunovant Inc is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. Its focus is on developing IMVT-1402, a potential inhibitor of the neonatal fragment crystallizable receptor (FcRn), to address autoimmune diseases driven by high levels of pathogenic immunoglobulin G (IgG) antibodies. FcRn is involved in preventing the degradation of IgG antibodies, and inhibition of FcRn has been shown to reduce levels of total IgG and pathogenic IgG antibodies. The company operates in a single operating segment, which includes all activities related to the research, development and manufacturing of its product candidates. |
